Lung adenocarcinoma
Conditions
Interventions
single arm: TKI combined with Anlotinib monotherapy
Sponsors
Henan Cancer Hospital / Affiliated Cancer Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) aged 18-75 years, 0-1 ECOG PS score; 2) pathologically diagnosed as advanced (stage IIIB/IV) non-small cell lung cancer with measurable lesions; 3) disease progression after being treated with an EGFR sensitive mutation (19del/L858R) and receiving a single generation of EGFR TKI (according to RESIST criteria); 4) biopsy can be performed after disease progression, and EGFR test T790M mutation is negative; 5)The functions of other major organs meet the requirements.
Exclusion criteria
Exclusion criteria: 1) small-cell carcinoma mixed with non-small-cell carcinoma, central, hollow lung squamous carcinoma, or patients with non-small-cell lung cancer accompanied by hemoptysis (>50 mL/day); 2) patients with brain metastasis with symptoms or with symptom control time less than 2 months; 3) patients whose tumors have invaded important blood vessels or who, according to the researcher's judgment, are likely to have massive bleeding during the follow-up study; 4) patients with any physical signs or history of bleeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease control rate;Overall survival; | — |
Countries
China
Contacts
Public ContactHuijuan Wang
Henan Cancer Hospital / Affiliated Cancer Hospital of Zhengzhou University
Outcome results
None listed